Health
Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates
Company recently announced definitive agreement to be acquired by AstraZeneca FPI-2265 Phase 2/3 registrational program for patients with metastatic castration-resistant prostate cancer (mCRPC) expected to begin in Q2 2024 Interim data from TATCIST s
By: cision
- Mar 21 2024
- 0
- 0 Views
ONLY AVAILABLE IN PAID PLANS